v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue $ 1,256 $ 828
Operating expenses:    
Cost of revenue 1,625 1,551
Sales and marketing 5,002 4,069
General and administrative 5,432 6,162
Amortization of acquired intangible assets 105 105
Research and development 1,206 1,428
Total operating expenses 13,370 13,315
Operating loss (12,114) (12,487)
Other income (expense):    
Interest income 70 66
Interest expense (6) (9)
Change in fair value - Senior Secured Convertible Note (1,859) (14,478)
Other income (expense), net (1,795) (14,421)
Loss before provision for income tax (13,909) (26,908)
Provision for income taxes 0 0
Net loss attributable to Lucid Diagnostics Inc. (13,909) (26,908)
Less: Series B Convertible Preferred Stock dividends earned (9,719) (9,110)
Net loss attributable to Lucid Diagnostics Inc. common stockholders $ (23,628) $ (36,018)
Net loss per share attributable to Lucid Diagnostics Inc. common stockholders - basic and diluted (in dollars per share) [1] $ (0.17) $ (0.52)
Weighted average common shares outstanding, basic and diluted (in shares) 140,096,782 68,796,392
[1] Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.